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n this report, we summarize the findings from the confer-
nce on Emerging Infectious Diseases and Biological Ter-
orism Threats: The Clinical and Public Health Implica-
ions for the Prevention and Control of Cardiovascular
iseases, which was sponsored by the American College of
ardiology Foundation (ACCF), American Heart Associ-
tion (AHA), and Centers for Disease Control and Preven-
ion (CDC). The conference, held on August 13, 2004, at
he Heart House in Bethesda, Maryland, allowed for open
iscussion, constructive commentary, and the formulation
f summary statements resulting in the documents pre-
ented in the accompanying reports. The primary objectives
f the conference were to review 1) the direct clinical
ardiovascular implications of emerging infectious diseases
nd biological terrorism threats; 2) the indirect or secondary
ardiovascular implications of biological terrorist events or
reparedness strategies for potential bioterrorist events; 3)
he best practices for managing suspected cardiovascular
omplications associated with emerging infectious diseases
nd biological terrorism threats; and 4) the basic, clinical,
nd population science research and training needs in this
rena.
Four tasks forces were formed to address each of the 4
onference objectives. Each task force was charged with
roducing a report summarizing the relevant conference
ndings, as well as developing summary statements and
uture directions for the prevention and control of cardio-
ascular diseases and complications during an actual bio-
errorist attack.
In this executive summary and the accompanying task
orce reports, the term “emerging infectious diseases” in-
ludes both emerging (newly recognized, clinically distinct
nfectious diseases) and re-emerging infectious diseases
known infectious diseases whose reported incidence is
ncreasing in a given place or among a specific population).
he term “biological terrorism threats” includes the poten- pial intentional release of both infectious and noninfectious
e.g., toxic) agents in terrorist acts. Overall, the primary
ocus is on the clinical and public health implications of
merging infectious diseases and biological terrorism threats
or the cardiovascular system. The cardiovascular implica-
ions of other disasters and threats involving radiological or
hemical substances are not primary subjects of these
eports.
ackground
he threats of emerging infectious diseases and the poten-
ial intentional use of biological agents in terrorist acts are
mportant national security concerns (1). They also pose
ajor challenges for clinical medicine and public health in
ddressing preparedness and response (1,2). The Institute of
edicine alone has held several workshops and published
ore than a dozen related reports over the last decade on
hese challenges (3), but none of them specifically addresses
he cardiovascular implications of this threat. Both emerg-
ng infectious diseases and biological terrorism threats are
art of the spectrum of “microbial threats,” including
stablished infectious diseases (4).
Reports on population-based surveillance at several CDC
.S. Emerging Infections Program sites for unexplained
eath and critical illness of possible infectious causes in the
.S. in 1995 to 1998 identified cardiac signs and symptoms
s the third most common clinical presentation (5). Yet,
espite the important advances in the scientific understand-
ng of these diseases and the extent of national public health
ctivities in preparedness related to potential intentional
eleases of biological agents, strategies to address the poten-
ial direct and indirect cardiovascular effects of these agents
n the evaluation and management of persons with cardio-
ascular diseases or risk factors remain largely unexplored.
Questions that remain to be answered include: What
hould the cardiovascular specialist and other health care
roviders who treat patients with heart disease know about
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oms, and other clinical cardiovascular manifestations of
nhalation anthrax or smallpox infection? Would physicians
eadily recognize the possible cardiovascular symptoms of
nfection with hantavirus (pulmonary syndrome), avian
nfluenza virus, or endocarditis and other cardiovascular
anifestations of brucellosis, tularemia, or Q fever? What
re the presenting manifestations of myopericarditis when it
omplicates smallpox pre-event vaccination? Which people
ith pre-existing cardiovascular disease should be excluded
rom preventive interventions, such as pre-event vaccina-
ion, against bioterrorist threats? What are the current
ecommendations for antimicrobial and other preventive
nterventions? The quest for answers to these questions
ormed the basis of the conference and the resulting
ummary and task force reports.
ASK FORCE I: Direct
ardiovascular Implications
f Emerging Infectious Diseases
nd Biological Terrorism Threats
ask Force I reviewed the direct clinical cardiovascular
mplications of emerging infectious diseases and infection
ith select agents designated to have potential for inten-
ional release (4,6) as listed and described on the CDC
mergency Preparedness and Response Web site (http://
ww.bt.cdc.gov/agent/agentlist.asp). The report presents
he CDC classification of bioterrorism agents and diseases
nto Categories A, B, and C on the basis of their ease of
issemination or transmission from person to person, po-
ential for causing high mortality or major public health
mpact, and/or requirement for special procedures or actions
uring public health preparedness. The Web site presents
he routes of infection, associated signs and symptoms, and
ecommended diagnostic procedures for the evaluation of
hese agents and diseases, which include anthrax, botulism,
lague, smallpox, tularemia, viral hemorrhagic fevers, ricin
oxin, brucellosis, Q fever, psittacosis, and salmonellosis.
Although many of these agents are uncommon in the
.S., and most of them do not primarily affect the cardio-
ascular system, some do have the potential to produce
irect cardiovascular effects and have substantial implica-
ions for individuals with underlying cardiovascular disease.
hese possibilities require that health care providers become
amiliar with the diseases these agents cause and their
mpact on the cardiovascular system.
In general, the known direct cardiovascular effects of
hese pathogens and biological toxins fall under 4 predom-
nant syndromes: 1) endocarditis, 2) myocarditis, 3) peri-
arditis, and 4) endarteritis. The clinical manifestations of
hese syndromes do not vary by microbiologic etiology.
hen infection is uncommon and unanticipated in certainopulations or geographic settings, or in the event of antentional release, these signs and symptoms could be
ndistinguishable from those of naturally occurring infec-
ions or the progression of underlying cardiovascular dis-
ase. In the case of aggressive pathogens, clinical evidence
ight develop within hours to days, whereas infection with
ess virulent microorganisms might produce more subtle,
ndolent, and initially nonspecific signs and symptoms over
eeks or months. Other direct cardiovascular manifesta-
ions that pose diagnostic and therapeutic challenges, espe-
ially in patients with established cardiovascular disease,
nclude fever, tachycardia, hemodynamic collapse, and other
ardiopulmonary effects of systemic toxicity or sepsis.
The report recommends that cardiovascular specialists
nd other health care providers who treat patients with heart
isease develop a general working knowledge of the high-
riority potential bioterrorist agents and their possible
odes of dissemination, the clinical presentation of infec-
ion, and recommended diagnostic evaluations. Health care
roviders should also become familiar with the federal, state,
nd local surveillance capabilities and networks of special-
zed laboratories that are part of national public health
reparedness. These resources are invaluable when exposure
o a potential bioterrorist agent is suspected. Continuing
edical education in these areas should be considered an
mportant aspect of national preparedness.
ASK FORCE II: Indirect and
econdary Cardiovascular Effects of
iological Terrorism Agents and Diseases
ask Force II addressed the indirect or secondary cardio-
ascular implications of bioterrorism threats and prepared-
ess strategies (e.g., immunization against smallpox using
he vaccinia vaccine). Key areas reviewed include the car-
iovascular effects of mass pre-event vaccination campaigns;
he pathophysiological basis for stress-related triggering of
cute cardiovascular events; and the capacity for large-scale
errorist events to overwhelm the emergency medical and
ealth care system, straining a community’s ability to
rovide timely care for patients with more conventional but
ime-dependent, medical, and surgical emergencies such as
cute cardiac events and stroke. The possible use of phar-
acologic prophylaxis in vulnerable populations is also
ddressed.
In addition, the effect of a terrorist attack on the health
are system, particularly as it relates to the care of patients
ith underlying cardiovascular disorders, will depend on
ow many victims survive and need significant medical care,
he nature of the attack, and how long the influx of patients
nd need for care continues. The report emphasizes that this
eed for surge capacity for all emergency situations must be
ddressed. One valuable model discussed is the congression-
lly funded emergency department renovation plan devel-
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rauma center serving the nation’s capitol (http://er1.org).
The report recommends further research on the cardio-
ascular complications of vaccines to determine whether
ndividuals at higher risk for adverse effects can be identified
rospectively and whether alternative preventive and thera-
eutic interventions should be offered to these individuals.
n addition, further study is needed on the links between the
sychological stress associated with bioterrorism and acute
ardiovascular events, particularly with respect to whether
ny additional prophylactic measures can be used for indi-
iduals at increased risk. The report also recommended
urther research on the chronic, long-term effects of bio-
errorist attacks. Policy considerations addressed include
trategies to increase surge capacity of hospitals, establish-
ent of appropriate surveillance systems, and widespread
doption of electronic health records with collection of
pecific, uniformly defined data elements that could facili-
ate the use of these data in a real-time national surveillance
ystem.
ASK FORCE III: Prevention and Control
f Cardiovascular Complications of
merging Infectious Diseases and Potential
iological Terrorism Agents and Diseases
ask Force III addressed the current best practices for the
revention and control of cardiovascular complications of
merging infectious diseases and potential bioterrorist
hreats. The report stresses the importance of early recog-
ition of signs and symptoms suggesting cardiovascular
nvolvement, appropriate management of acute events, and
ong-term care. It also discusses strategies for preventing the
pread of infection or disease in cardiac catheterization
aboratories and cardiac care units.
Best practices for patient management are reviewed in the
ontext of the 4 predominant cardiovascular syndromes
endocarditis, myocarditis, pericarditis, and endarteritis)
ssociated with emerging infectious diseases and potential
iological threats, as well as their potential metabolic,
rrhythmogenic, and hemodynamic impact on the cardio-
ascular system. Current guidelines for pre-event vaccina-
ions, postexposure prophylaxis where available, protection
f health care workers, and the role of cardiovascular
pecialists and other health care providers in bioterrorism
reparedness are also discussed.
The report recommends that all patients with suspected
accinia-associated heart disease undergo a comprehensive
hysical examination to identify potential pericardial rub or
vidence of heart failure and vaccinia rash, and to collect
aseline cardiac diagnostic data including electrocardio-
ram, chest X-ray, troponin test, and creatinine kinase-MB.
he report emphasizes that although the treatment for
ericarditis is generally symptomatic, myopericarditis with ievere left ventricular dysfunction may require invasive
tudies. Most cases of myopericarditis after vaccinia vacci-
ation are mild and resolve with supportive care, but in the
nusual case of severe left ventricular dysfunction, endo-
yocardial biopsy can help define the mechanism of myo-
arditis (7). The treatment for endocarditis and endarteritis
esulting from vaccinia vaccination should follow current
linical guidelines (8).
Current recommendations for delivering pre- and post-
vent vaccinia vaccination, as well as postexposure antimi-
robial prophylaxis, are presented. In general, persons who
hould not receive pre-event vaccination for smallpox in-
lude clinically immunocompromised persons; people with
ife-threatening allergies to latex or to the smallpox vaccine
r any of its ingredients; those with established cardiovas-
ular disorders, including congestive heart failure, ischemic
r dilated cardiomyopathy, or a history of myocarditis or
ericarditis; and persons with 3 or more risk factors for
oronary heart disease (http://www.bt.cdc.gov/agent/
mallpox/vaccination/heartproblems.asp).
The report highlights the current resources available to
linicians including materials and tools from the CDC and
ther federal agencies. For example, the CDC has estab-
ished a free registry to provide clinicians with real-time
nformation to help prepare for (and possibly respond to)
errorism and other emergency events. Participants receive
egular e-mail updates on terrorism and other emergency
ssues and on training opportunities relevant to clinicians
http://www.bt.cdc.gov/clinregistry/index.asp; http://
ww.bt.cdc.gov/agent/smallpox/clinicians.asp#register).
Patients suspected to have an emerging infectious disease
r be infected with an organism considered a bioterrorism
isk—including those with a high likelihood of airborne or
lood transmission—may need to undergo special cardiac
rocedures in a cardiac catheterization laboratory or cardiac
are unit. The report discusses the infection control mea-
ures needed to avoid nosocomial spread of infection in
hese settings, including education for hospital personnel,
ersonal protective measures, and environmental safety
easures.
ASK FORCE IV: Cardiovascular Effects
f Emerging Infectious Diseases and
iological Terrorism Threats: Basic,
linical, and Population Science
esearch and Training Needs
ask Force IV addressed gaps in the basic, clinical, and
opulation science research available to guide best practices
or the prevention and control of cardiovascular complica-
ions resulting from emerging infectious diseases and bio-
ogical terrorism threats. The report discusses the impor-
ance of epidemiologic studies and an appropriate research
nfrastructure for surveillance and response. Also discussed
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are to those experiencing cardiovascular complications
rom bioterrorist events.
The report notes that translational and interdisciplinary
esearch approaches are required to compile the information
rom animal, human, and population-based studies needed
o achieve a comprehensive understanding of how to iden-
ify, prevent, and treat the potential direct and indirect
ardiovascular effects of these agents. Needed measures
nclude syndromic surveillance (9,10), studies of the poten-
ial cardiovascular complications of immunization, and the
se of animal models to study the effect of potential
ioterrorist agents on atherosclerotic plaques, the coagula-
ion system, circulatory components, and the conduction
ystem. In particular, the potential role of these agents in
riggering acute destabilization of vulnerable plaques, lead-
ng to acute coronary syndromes or contributing to athero-
clerosis progression (11) deserve further study.
The report urges cardiovascular research scientists, aca-
emic institutions, and the cardiovascular professional soci-
ties to form strategic partnerships with federal agencies
hat fund biodefense research. Such partnerships could
ddress these cardiovascular research needs and strengthen
he public health infrastructure (12) for future research on
he cardiovascular implications of emerging infectious dis-
ases and biological terrorism threats. The report stresses
he need to define and implement environmental safety
rocedures for catheterization laboratories and coronary care
r intensive care units that may care for patients infected
ith highly contagious agents. In addition, the impact of
accination, anti-toxin and -infective therapy, and post-
xposure antimicrobial prophylaxis in patients with pre-
xisting cardiovascular disease deserve further study.
ask Force Reports
he reports of each of the 4 task forces follow this executive
ummary. The authors of each report summarize the rele-
ant conference discussions, as well as the appropriate
iterature. In addition, the authors offer suggestions for
mproving our understanding of the cardiovascular effects of
otential bioterrorist agents, enhancing our ability to pre-
ent and treat these effects, and better preparing first
esponders and health care providers to quickly identify andreat the cardiovascular manifestations that could follow a
uture bioterrorist attack. These suggestions and the opin-
ons expressed in the reports are those of the authors and
hould not be construed as necessarily representing the
iews of their affiliated institutions, the ACCF, AHA, or
he CDC.
EFERENCES
1. Gerberding JL, Hughes JM, Koplan JP. Bioterrorism preparedness
and response: clinicians and public health agencies as essential part-
ners. JAMA 2002;287:898–900.
2. Hamburg MA. Bioterrorism: a challenge to public health and medi-
cine. J Public Health Manag Pract 2000;6:38–44.
3. Institute of Medicine, Board on Global Health, Forum on Microbial
Threats. Biological Threats and Terrorism: Assessing the Science and
Response Capabilities. Available at: http://www.iom.edu/CMS/3783/
3924/4326.aspx. Accessed on December 21, 2006.
4. Institute of Medicine. Emerging Infections: Microbial Threats to
Health in the United States. Washington, DC: National Academy of
Sciences, 1992.
5. Hajjeh RA, Relman D, Cieslak PR, et al. Surveillance for unexplained
deaths and critical illnesses due to possibly infectious causes, United
States, 1995–1998. Emerg Infect Dis 2002;8:145–53.
6. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public
health assessment of potential biological terrorism agents. Emerg
Infect Dis 2002;8:225–30.
7. Murphy JG, Wright RS, Bruce GK, et al. Eosinophilic-lymphocytic
myocarditis after smallpox vaccination. Lancet 2003;362:1378–80.
8. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis:
diagnosis, antimicrobial therapy, and management of complications: a
statement for healthcare professionals from the Committee on Rheu-
matic Fever, Endocarditis, and Kawasaki Disease, Council on Cardio-
vascular Disease in the Young, and the Councils on Clinical Cardiol-
ogy, Stroke, and Cardiovascular Surgery and Anesthesia, American
Heart Association—executive summary: endorsed by the Infectious
Diseases Society of America. Circulation 2005;111:3167–84.
9. Yih WK, Caldwell B, Harmon R, et al. National Bioterrorism
Syndromic Surveillance Demonstration Program. MMWR Morb
Mortal Wkly Rep 2004;53 Suppl:43–9.
0. Loonsk JW. BioSense—a national initiative for early detection and
quantification of public health emergencies. MMWR Morb Mortal
Wkly Rep 2004;53 Suppl:53–5.
1. Libby P, Egan D, Skarlatos S. Roles of infectious agents in athero-
sclerosis and restenosis: an assessment of the evidence and need for
future research. Circulation 1997;96:4095–103.
2. Grantmakers in Health. Strengthening the public health system for a
healthier future. Issue Brief 2003;17:1–41.
PPENDIX 1. ACCF/AHA/CDC CONSENSUS
ONFERENCE REPORT ON EMERGING INFECTIOUS
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XECUTIVE SUMMARY—RELATIONSHIPS
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